VJHemOnc is committed to improving our service to you

SOHO 2020 | Management of adult T-ALL

VJHemOnc is committed to improving our service to you

Nitin Jain

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the management of patients with T-cell acute lymphoblastic leukemia (T-ALL), a rare subtype of ALL, including first-line therapy with chemo-immunotherapy such as nelarabine along with hyper-CVAD. Dr Jain also highlights venetoclax, a BCL-2 inhibitor, as a possible strategy for patients with T-ALL as evaluated in a Phase I study in combination with mini-hyper-CVD. Dr Jain continues to discuss the importance of identifying ETP-ALL patients, a subtype of T-ALL that is associated with higher-risk and requires transplant in first complete remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter